Brief: Citius Pharmaceuticals Announces Positive Results From The Phase 2B Study Of Halo-Lido For The Treatment Of Hemorrhoids
20/06/2023 17:29
June 20 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE
PHASE
2B STUDY OF HALO-LIDO (CITI-002) FOR THE TREATMENT OF
HEMORRHOIDS
* CITIUS PHARMACEUTICALS INC - CITI-002 PROVIDES A
MEANINGFUL
REDUCTION IN SYMPTOM SEVERITY WHEN COMPARED TO INDIVIDUAL
COMPONENTS ALONE
* CITIUS PHARMACEUTICALS INC - CITIUS TO SCHEDULE END OF
PHASE 2
MEETING WITH FDA
* CITIUS PHARMACEUTICALS INC - NO REPORTED SIGNIFICANT
ADVERSE
EVENTS AND CITI-002 WAS WELL TOLERATED BY PATIENTS IN STUDY
Source text for Eikon: ID:nPnbG30kja
Further company coverage: CTXR.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules